From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Latest Views & News

Tom Winnifrith Bearcast - will Parsley Box come clean?

By Tom Winnifrith | Thursday 11 August 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I start with a bity of my travel adventures. I was in bed by 3 AM last night after the previous night's 5 AM. If I ever say that I am driving from Greece to Wales in 2.5 days again you can shoot me.  Then I remind you that it is less than a month to ShareStock so book your seats on the greenest lawn in Wales NOW. Then I look in detail at Revolution Beauty (REVB), Wildcat Petroleum (WCAT), I have a hot rumour on Parsley Box (MEAL) and I comment on GSK (GSK) and the Zantac issue. or non issue. Any more carcinogens with your medication vicar?

You must be a paid subscriber to listen to Bearcast
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

WIX

How is Wickes getting along?

Friday »

TERN

Tern – Is There More Bad News On The Way?

Thursday »

ZYT

Zytronic – now a recovery Buy?

 

YGEN

Buy Yourgene - target 0.6p

 

ROO

Keep avoiding Deliveroo shares

Friday »

THS

Tharisa – Q1 report, still a value Buy